Why GSK plc’s (GSK) Stock Is Up 6.56%
As of Tuesday, July 28, GSK plc’s GSK share price has surged by 6.56%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Commentary & Analysis
Why GSK plc’s (GSK) Stock Is Down 6.39%
As of Wednesday, April 29, GSK plc’s GSK share price has dipped by 6.39%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why GSK plc’s (GSK) Stock Is Up 6.34%
As of Wednesday, February 04, GSK plc’s GSK share price has surged by 6.34%, which has investors questioning if this is right time to sell.Jenna Brashear
Why GSK plc’s (GSK) Stock Is Up 6.28%
As of Wednesday, October 29, GSK plc’s GSK share price has surged by 6.28%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why GSK plc’s (GSK) Stock Is Down 5.04%
As of Friday, October 24, GSK plc’s GSK share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | GSK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $92,792.9 | $519.2 | 96% |
|
| Shares Out (Mil) | 5,389.4 | 42.8 | 99% |
|
| Institutional Ownership | 99.9% | 82.8% | 96% |
|
| Float (Mil) | 3,882.4 | 44.4 | 98% |
|
| Beta | 0.29 | 0.71 | 17% |
|
| Avg Daily Volume (000s) | 5,792 | 394 | 93% |
|
| Price Change (52-week) |
7.3% | 60.2% | 60% |
|
| Growth | GSK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.7% | 6.1% | 40% |
|
| Net Income (5yr) | (0.4%) | (2.0%) | 39% |
|
| EPS (5yr) | (0.8%) | 15.0% | 30 |
|
| Dividends (5yr) | (8.2%) | 0.0% | 77% |
|
| Cash Flow (5yr) | (19.7%) | (15.1%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 5 | 5 | |
| Current EPS | $1.328 | $4.734 | $4.941 | |
| Month Ago EPS | $1.352 | $4.793 | $4.980 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $1.414 | $4.787 | $5.128 | |
| Year/Year Chg | 835.2% | 153.4% | 171.4% | |
| Financials | GSK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $44,053 | $416 | 96% |
|
| Net Income (TTM) (Mil) | $6,396 | ($11) | 97% |
|
| EPS (TTM) | $1.590 | ($0.700) | 67% |
|
| Operating Cash Flow (TTM) (Mil) | $11,054 | ($7) | 98% |
|
| Net Cash Flow (TTM) (Mil) | ($562) | $6 | 5% |
|
| Long-Term Debt (Q1) (Mil) | $18,578 | $6 | 95% |
|
| Enterprise Value (Q1) (Mil) | $120,542 | $494 | 97% |
|
| Valuation | GSK | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.96 | 2.31 | 88% |
|
| P/E | 29.7 | 17.4 | 70% |
|
| Dividend Yield | 3.9% | 0.0% | 89% |
|
| PEG (5yr hist) | 11.9 | 1.1 | 95% |
|
| Ratios | GSK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 73.5% | 69.4% | 84% |
|
| Net Margin | 14.5% | 3.2% | 71% |
|
| ROA | 7.8% | (22.2%) | 82% |
|
| ROE | 29.3% | (21.4%) | 87% |
|
| Liabilities to Assets | 72.2% | 32.8% | 68% |
|
| F-Score | 8 | 3 | 93% |
|
GSK plc did not pass any screens on 10/9/2026.
